Organization
Corcept Therapeutics
22 clinical trials
Clinical trial
Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of RelacorilantStatus: Recruiting, Estimated PCD: 2024-03-29
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1b, Open-Label Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid ProductionStatus: Completed, Estimated PCD: 2023-10-17
Clinical trial
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-07-19
Clinical trial
A Phase 1, Open-Label, Fixed-Sequence Crossover Study to Evaluate the Effect of a Strong Inhibitor of Cytochrome P450 2C19 on the Pharmacokinetics of Miricorilant in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-02-23
Clinical trial
A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT125236 in Healthy Subjects, With an Optional Pharmacological Effects CohortStatus: Completed, Estimated PCD: 2023-02-03
Clinical trial
Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid TumorsStatus: Completed, Estimated PCD: 2020-05-12
Clinical trial
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerStatus: Completed, Estimated PCD: 2023-01-09
Clinical trial
An Open-label, Multiple-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of RelacorilantStatus: Completed, Estimated PCD: 2020-12-14
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)Status: Completed, Estimated PCD: 2023-01-31
Clinical trial
An Open-Label, Repeat-Dose Study to Evaluate the Pharmacokinetics of Orally Administered CORT125134 Using the Current Capsule Formulation in Healthy SubjectsStatus: Completed, Estimated PCD: 2017-11-15
Clinical trial
An Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of the Phase 2 Formulation of CORT125134 Capsules in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2016-04-27
Clinical trial
A Phase 1, Randomized, Open-Label, Single-Dose, Three-Way Crossover Study to Evaluate The Effect of Food on the Oral Bioavailability of Relacorilant in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-11-16
Clinical trial
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)Status: Terminated, Estimated PCD: 2021-08-23
Clinical trial
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of RelacorilantStatus: Completed, Estimated PCD: 2024-04-08
Clinical trial
An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing SyndromeStatus: , Estimated PCD: 2025-12-01
Clinical trial
A Phase 1, Open-label, Single-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantStatus: Recruiting, Estimated PCD: 2024-12-31